Kalshi Is Letting People Bet On Clinical Trials And FDA Drug Decisions
Online prediction market platform Kalshi has launched a new suite of markets allowing users to bet on the outcomes of pharmaceutical clinical trials and FDA approval decisions. The platform has already accepted over $100,000 in wagers since launch. The move raises novel questions about the intersection of financial speculation and drug development timelines.
The Atomic take
Prediction markets on trial readouts and FDA calendars create a public price for drug outcomes that has historically lived only inside biotech trading desks and analyst models, which could pull retail attention toward binary catalysts like PDUFA dates and Phase 3 primary endpoints. The immediate concern is information asymmetry: insiders with early access to trial data or advisory committee sentiment could quietly profit, inviting the same insider-trading scrutiny that already dogs biotech equities. Watch whether the SEC or FDA weighs in on these contracts, and whether $100,000 in early wagers grows enough to actually move sentiment around specific companies.
Read the full story at Forbes →Know where humanity is headed.
Five forces. One brief. Free, every Monday morning.
Get The Atomic Five